Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs EverSlim

Two GLP-1 desks, one scoreboard. We put MadeMed and EverSlim head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
Higher Brief ScoreNo. 12 · Grade B+

EverSlim

Visit EverSlim Full brief →

The verdict

EverSlim takes this head-to-head.

EverSlim scores 87 to 86 on our six-factor Brief Score — EverSlim is a US telehealth program offering doctor-prescribed, compounded GLP-1 weight-loss medication delivered to your door.

That doesn't make MadeMed a bad call — it's best for readers who want to know the exact cost of a titrated dose before starting, and who intend to climb to a full dose. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
78
Supply Reliability
84
91
Transparency
94
94
Access Breadth
76
90
Clinical Oversight
84
84
Track Record
82
82
MadeMedBrief Score 86 · 87EverSlim

Price, coverage & the tracker

MadeMedEverSlim
Brief Score86/100 (B)87/100 (B+)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)$127/mo
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)$183/mo
Coverage40 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

EverSlim: New to the tracker on 1 August 2026. The published line reads $127/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.